OBJECTIVE

2

To establish the path-based management mode of 5-hydroxytryptamine-3 receptor antagonist （5-HT

3

RA） in chemotherapy patients， and to improve the rationality of medication in chemotherapy patients.

METHODS

2

5-HT

3

RA standardized drug use control rules were formulated， with the help of medical intelligence and decision support （MINDS） system， path-based management was carried out for chemotherapy patients using 5-HT

3

RA in the form of whole-process information capture and prescription pre-review， and whole-process intervention was implemented on medication indications， usage and dosage， course of treatment， etc. The intervention effect was analyzed by comparing the changes in the use of 5-HT

3

RA without indication， unreasonable usage and dosage， repeated medication， unreasonable course of treatment， and per capita drug cost before and after the implementation of path-based management.

RESULTS

2

A total of 9 181 patients were included. After the implementation of path-based management， the proportion of unindicated drugs decreased by 0.48%， and the rate of unreasonable single dosage， unreasonable frequency， repeated medication， unreasonable treatment course （5-HT

3

RA still used 3 days after chemotherapy） decreased by 10.48%， 0.65%， 1.33% and 0.34%； per capita cost of 5-HT

3

RA decreased by 13.72 yuan； there were statistical significance （

P

＜0.05）.

CONCLUSIONS

2

5-HT

3

RA path-based management mode effectively improves the rationality of medication and provides a new idea for rational clinical drug use.